Study: Weight loss drugs could reduce cancer risk
(NewsNation) — New data released shows widely used GLP-1 diabetes drugs like Ozempic could reduce the risk of obesity-related cancers like colorectal cancer.
The study looked at 170,030 adults with obesity and diabetes from 43 health systems in the United States, and found that between the groups treated with DPP-4 drugs and GLP-1s, there were 16% fewer colon cancer cases and 28% fewer rectal cancer cases in the group prescribed GLP-1s.
Nearly half of US states risk a caregiving crisis, study warns
The data showed GLP-1 drugs were much more effective than other types of drugs used to treat diabetes, known as dipeptidyl peptidase-4 inhibitors, which don't have the same weight loss effect as GLP-1s.
'Patients who took GLP-1 receptor agonists had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took a DPP-4 inhibitor,' the authors of the study said.
The authors of the study say they hope to continue their research for a longer period of time and include people who do not have diabetes.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ('Treace' or the 'Company') (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, 'Zimmer') (NYSE: ZBH), alleging infringement of 4 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. 'Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,' said John T. Treace, Chairman, CEO and Founder of Treace. 'Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.' Treace's patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram. Contacts:Treace Medical ConceptsMark L. HairChief Financial Officermhair@ 373-5940 Investors:Gilmartin GroupPhilip Trip Taylor IR@
Yahoo
an hour ago
- Yahoo
More Americans turning to weight loss drugs to shed weight
HARTFORD, Conn. (WTNH) — More Americans are turning to medical weight loss drugs to lose weight. Before you start, you may want to think about speaking with a registered dietitian nutritionist. Hartford HealthCare's Cody Krawec, a clinical nutrition manager at St. Vincent's Medical Center, joined Good Morning Connecticut at 9 a.m. to explain. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Bug-eyed telescope ready to find Earth-smashing asteroids
It's only a matter of time before a catastrophically sized asteroid barrels towards Earth again. Until very recently in human history, there was no way of knowing if one was hurtling towards us, much less do anything to alter its path. Now, international space agencies and disaster preparedness experts have powerful tools to keep watch over the skies—and the newest aide just opened its bug-inspired compound 'eye.' According to the European Space Agency, the Flyeye-1 telescope recently completed its 'first light' test at the Italian Space Agency's Space Geodesy Center, located about 160 miles east of Naples. Soon, it and as many as three other similar installations around the world will work in tandem to provide comprehensive, automated surveys of space every night to scan for cosmic threats. 'The earlier we spot potentially hazardous asteroids, the more time we have to assess them and, if necessary, prepare a response,' explains Richard Moissl, Head of ESA's Planetary Defence Office. 'ESA's Flyeye telescopes will be an early-warning system, and their discoveries will be shared with the global planetary defence community.' Similar to an insect's vision (hence its name), Flyeye captures incoming light through its 3.3-foot-wide primary mirror. That light is divided into 16 independent channels, all equipped with their own secondary lens and detector cameras designed to flag extremely faint objects. Flyeye's automated observation schedule is designed to factor in variables such as lunar brightness along with other survey telescopes like NASA's ATLAS, the Zwicky Transient Facility, and the forthcoming Vera Rubin Telescope. So what happens if Flyeye spies a suspicious space rock out there in deep space? The plan is for experts at ESA's Near-Earth Object Coordination Center (NEOCC) to review and verify any potential concerns. If the situation warrants further investigation, the NEOCC will then forward their report to the Minor Planet Center, a global hub for asteroid data. Subsequent research will lead to international contingency planning, which could involve any number of solutions, such as smacking the asteroid off course with a targeted spacecraft launch. Before that can happen, Flyeye needed to demonstrate its up to the task. For its first light test, Flyeye focused on multiple known asteroids, including 2025 KQ. Astronomers discovered the space rock only two days earlier, offering direct proof that the telescope is already capable of rapid follow-up observations. 'These images of the sky above the ancient stone hills of Matera, Italy, are more than just a test—they are proof that Flyeye is ready to begin its mission,' ESA said in its announcement. Flyeye-1 is now on its way for installation on Monte Mulfara in Sicily. If all goes according to plan, the telescope's first sibling will be up and running sometime in 2028.
